Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) reported revenue of $2.8 million for the nine months ended Sept. 30, 2026, a 167% increase from $1.05 million in the prior-year period, according to the company's latest financial disclosure. The gain reflects the expansion of its contract development and manufacturing organization, including the February acquisition of Recipharm Israel, and matters because it shows the Israeli biopharmaceutical company converting its manufacturing buildout into recurring service revenue rather than relying solely on an early-stage therapeutic pipeline.
The order book offers the clearest signal of durability. Scinai reported approximately $8.32 million in committed customer orders as of Nov. 4, 2026, up more than 330% from year-end 2025. That figure includes an expanded U.S. customer agreement carrying roughly $5.1 million in committed base service fees, a concentration that underscores both the scale of the win and the company's dependence on a small number of large clients. For a CDMO still establishing its commercial footing, contracted backlog of this size provides visibility that headline revenue alone does not.
Profitability remains a work in progress. Scinai posted an operating loss of $6.56 million and a net loss of $390,000, with the latter narrowed by a $6.4 million noncash bargain purchase gain tied to the Recipharm Israel acquisition. That accounting benefit flatters the bottom line without reflecting cash generation, so investors will need to watch whether operating losses compress as manufacturing utilization rises.
Balance sheet strength is the other pillar of the story. Scinai generated approximately $5.3 million in net proceeds from October financing transactions, bringing reported bank balances to about $8.1 million as of Oct. 27. Management expects sufficient operating liquidity through late 2027 based on current projections and anticipated customer payments, with additional clinical manufacturing work potentially extending the runway into 2028. That guidance matters because it reduces near-term dilution risk and gives the company room to execute on its order backlog.
Scinai operates a dual model: a CDMO business serving biotechnology and pharmaceutical clients through facilities in Jerusalem and Yavne, and an immunology-focused therapeutic development platform advancing candidates licensed from the Max Planck Society and PinCell S.r.l. The services arm now appears to be the nearer-term value driver, funding operations while the pipeline matures. Full details are available in the full press release, and ongoing updates are posted in the company's newsroom at https://ibn.fm/SCNI.
The announcement was distributed through InvestorWire, part of the Dynamic Brand Portfolio at IBN, which provides editorial syndication to 5,000+ outlets alongside social media distribution. Terms governing that content are set out in the InvestorWire disclaimer.


